menu toggle

Insights

ThinkLive-web-hero-background-1200x800

Insight

Pharma in the field: Barrett's story

Xcenda
February 2024

4 people having a discussion

Insight

Work worth doing: Innovative field solutions

AmerisourceBergen
December 2023

female speaking to medical audience

Insight

Essential skills for outsourced field solutions teams

AmerisourceBergen
November 2023

US capitol color

Insight

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

AmerisourceBergen
October 2023

Washington DC Capital

Insight

First 10 drugs for Medicare price negotiation announced under IRA

Corey Ford, MHA
August 2023

Abstract

Insight

Reimbursement considerations for home infusions

Xcenda
June 2023

Parent and child reading a book

Insight

Copay accumulator adjustment programs significantly increase patient financial burden

Xcenda
May 2023

Close-up of two business women shaking hands

Insight

How to forge stronger working relationships with payers

Warren Dunn
AmerisourceBergen
March 2023

abstract-brand-colors-texture

Insight

The essential guide to drug commercialization

AmerisourceBergen
February 2023

HTA Quarterly Logo

Insight

HTA Quarterly | Summer 2023

Xcenda
November 2022

HTA Quarterly Logo

Insight

HTA Quarterly | Winter 2022

Xcenda
October 2022

HTA Quarterly Logo

Insight

HTA Quarterly | Winter 2022

Xcenda
October 2022

vaccines on top of US dollars

Insight

Improve outcomes and reduce costs for emerging therapies

AmerisourceBergen
October 2022

HTA Quarterly Logo

Insight

HTA Quarterly | Fall 2022

HTA Quarterly
August 2022

innovative agreements

Insight

Innovative agreements: Exploring alternative payment models

AmerisourceBergen
July 2022

Business meeting

Insight

Navigating reimbursement and access challenges for novel cell and gene therapies

Amanda OHora
July 2022

abstract waves

Insight

Research poster: The current impact of ICER assessments on payer decision making

Xcenda
June 2022

Differentiate your product with FormularyDecisions

Insight

Differentiate your product with FormularyDecisions®

Xcenda
April 2022

Healthcare provider with Canadian flag

Insight

The drug reimbursement environment in Canada: An overview

Xcenda
February 2022

Xcenda_2_3_Card-02

Insight

HTA Quarterly | Spring 2022

Xcenda
February 2022

health insurance claim form

Insight

Building your field reimbursement and access team: The translational experience and skills that matter most

AmerisourceBergen
September 2021

abstract lines

Insight

Equity considerations in US value assessment: Opportunities ahead

Xcenda
August 2021

abstract-brand-colors-texture

Insight

What manufacturers need to know about reimbursement and patient support for cell and gene therapies

Ana Stojanovska; Myra Reinhardt
Biopharma Services
July 2021

woman on smartphone in urban setting

Insight

Navigating the payer landscape for digital therapeutics

Lash Group
June 2021

scanning pharmacy product

Insight

Copay accumulators and the impact on patients

Corey Ford, MHA
June 2021

abstract-blues-tech

Insight

Work worth doing: FormularyDecisions

Laurie Fazio
Xcenda
May 2021

Strategic partnerships for unlocking product potential ebook

Insight

Ebook: Strategic partnerships for unlocking product potential

AmerisourceBergen
April 2021

pills on green textured background

Insight

Buy-and-bill vs. self-administered: Field services remove barriers across access points

Rod Bryant, MS; MarSha Lewers
March 2021

Market access professionals

Insight

Webinar: uptake or heartbreak with biosimilars? Progress and perspectives

Xcenda
February 2021

xcenda field services working on project

Insight

Checklist: Four things to look for in a field services partner

Xcenda
February 2021

woman with mask at computer

Insight

Launching field services in the midst of COVID-19

Xcenda
February 2021

insurance card and tablet

Insight

Case study: an innovative field reimbursement program expands patient access

Xcenda
January 2021

field-services-patient-access-meeting

Insight

Evaluating the modern field reimbursement and access program: key considerations

Xcenda
December 2020

Doctor talking to patient

Insight

Pharma in the field: Heather's story

Xcenda
December 2020

lash group copay accumulator program

Insight

Webinar: the growing utilization of copay accumulator programs

Corey Ford, MHA; Dale Hanna
December 2020

telehealth visit

Insight

It’s the Healthcare of the Future: Telehealth Trends Beyond 2020

Xcenda
November 2020

Doctor talking to patient

Insight

Pharma in the field: Ashley's story

Xcenda
November 2020

insurance card and tablet

Insight

Pharma in the field: Tierra's story

Xcenda
November 2020

businessman with laptop reviewing a dashboard

Insight

Case study: Gaining payer attention through digital innovation

Xcenda
September 2020

Male doctor speaking to patient on a tablet

Insight

Solving access, reimbursement, and PAP awareness problems

Xcenda
August 2020

lightbulb shatter

Insight

Distant But Engaged: Transitioning to Virtual Training

Xcenda
May 2020

Pill in palm of hand

Insight

Impact of COVID-19 Pandemic on Patient Access Programs

Xcenda
April 2020

Insight

Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments

Xcenda
February 2020

biosims video thumb1

Insight

Video: Removing Barriers for Biosimilars

AmerisourceBergen
February 2020

Insight

How Digital Innovation Drives Improved Market Access Strategies

Xcenda
July 2019

Insight

Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions

Xcenda
June 2019

Insight

Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model

Xcenda
May 2019

Insight

Managing the Growing Expansion of Copay Accumulators

Corey Ford, MHA
March 2019

Insight

Original Report: Impact Analysis of ICER Formulary Implementation in Medicaid

Xcenda
March 2019

Insight

Medicare Part B: Do Providers Choose Treatment Based on Payment?

Xcenda
January 2019

What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.

Insight

Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries

Xcenda
December 2018

Insight

Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments

Xcenda
October 2018

Insight

Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?

Xcenda
September 2018

Insight

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Ana Stojanovska
Biopharma Services
June 2018

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

Insight

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Ana Stojanovska
Biopharma Services
June 2018

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Insight

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

AmerisourceBergen
April 2018

Insight

What Do Payers Think About Digital Health Technologies

AmerisourceBergen
September 2017

Insight

Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers

Xcenda
August 2017

Insight

Biosimilar Coding—Could There Be Billions in Hidden Savings?

Xcenda
August 2017

Loading...